Acute kidney injury (AKI) has been recognized as an independent risk factor for prolonged hospital stay, new-onset chronic kidney disease (CKD) and increased mortality rate[@b1][@b2]. Seriously, the prevalence of AKI is increasing in recent years[@b3][@b4]: nearly 3--20% for general inpatients, 30--60% for intensive care unit (ICU) patients.

To earlier and more accurate screen out the severe disease, diagnosis criteria for AKI have been updated three times: the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease) criteria in 2004 year, AKIN (Acute Kidney Injury Network) criteria in 2007 year, and the newly 2012 KDIGO (Kidney Disease Improving Global Outcomes) criteria[@b5][@b6][@b7]. It should be mentioned that all of the three criteria use the same kidney function assessment index: serum creatinine (Scr) and urine output.

However, both Scr and urine output are known as insensitive and nonspecific parameters for renal function evaluation. Thus, a great variety of bio-markers has been identified and then applied in the clinical settings in recent years[@b8][@b9][@b10]. Among the potential markers, serum cystatin C (Scys) performs a consistent accuracy in various conditions. For both the healthy individuals and CKD patients, Scys has ever been proposed as a superior marker to Scr to evaluate glomerular filtration rate (GFR)[@b11][@b12].

Recently, based on its physiological metabolism characteristics, that the life cycle of Scys is merely half of that of Scr (1.5--2 hours vs. 4 hours). Namely, once renal function is fluctuating, Scys changes much earlier than Scr[@b13][@b14]. Zhang, *et al*.[@b15] performed a meta-analysis to compare serum and/or urine cystatin C for diagnosis of AKI, and then they found Scys appeared to be a better biomarker in the prediction of AKI.

Since then, concerns focused on Scys for AKI prediction have been accelerating. However, with accumulating evidence, conflicting results have raised. Wan *et al*.[@b16] reported that the predict value (the area under the receiver operating characteristic curve, AUROC) of Scys was 0.974, with high sensitivity and specificity, which were similar in Liu's[@b17], Yim's[@b18] and other studies. In contrast, another studies indicated a negative results. GaygIsIz *et al*.[@b19] and Martensson *et al*.[@b20] found that the predict values (AUROC) of Scys was 0.67, with low sensitivity and specificity. Based on these controversial results, we conducted the present meta-analysis to investigate the overall diagnostic accuracy of Scys for AKI, and further identify which factors affecting its performance.

Results
=======

Literature search
-----------------

Our research initially identified 1693 citations, among which, 1537 were excluded as they were review articles, animal studies, laboratory reports, pediatric studies, not relevant and duplicate records. Thirty studies[@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45] finally met the inclusion criteria via full-text evaluation from 156 potentially eligible citations. Seven studies[@b21][@b22][@b23][@b24][@b25][@b26][@b27] were selected from the previous meta-analysis (Zhang, *et al*. 2011)[@b15] and an additional 23 studies[@b16][@b17][@b18][@b19][@b20][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45] were complemented in the present meta-analysis. A flow chart of the identification and selection process is shown in [Fig. 1](#f1){ref-type="fig"}.

Subjects characteristics and quality assessment
-----------------------------------------------

The main characteristics of the included studies were summarized in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}. A total of 4,247 patients (mean age 61.6 years, male 70.9%) from 15 countries were enrolled in the 30 studies. The overall AKI incidence was 23.1% (982/4247, varied from 6.0% to 54.3%). The top three settings prone to AKI were 32.3% after cardiac surgery, 28.5% in ICU/cardiac care unit (CCU) and 13.8% in contrast-induced nephropathy (CIN). The elderly and non-elderly patients suffered from an almost similar AKI prevalence (23.1% vs. 22.6%, *P* \> 0.05).

The second version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) plot demonstrated no significant bias had influenced the methodological quality of the included studies ([Fig. 2](#f2){ref-type="fig"}).

Predictive value of Scys for AKI
--------------------------------

The pooled diagnostic accuracy of Scys was listed in [Table 3](#t3){ref-type="table"} and [Fig. 3](#f3){ref-type="fig"}. The overall diagnostic sensitivity and specificity was 0.82 (95% CI: 0.75 to 0.87) and 0.82 (95% CI: 0.78 to 0.86), respectively. The pooled positive and negative likelihood ratios were 4.6 (95% CI: 3.6--5.9) and 0.22 (95% CI: 0.16--0.31), respectively and the DOR was 21 (95% CI: 12--35). The overall area under the receiver operating characteristic curve (AUROC) reached 0.89. All the results above revealed a good diagnostic accuracy of Scys to screen out AKI ([Fig. 4](#f4){ref-type="fig"}).

Threshold analysis and meta-regression analysis
-----------------------------------------------

The Spearman correlation coefficient between the pooled sensitivity and 1-specitity was −0.277 (P = 0.131), indicating no threshold effect. Meta-regression analysis showed the following factors irrelevant with accuracy of Scys for AKI: settings, diagnostic criteria, region, Scys determination method, participant mean age, gender, sample size ([Table 3](#t3){ref-type="table"}).

Influence factors affecting Scys of AKI
---------------------------------------

Various Scys blood sampling point-in-time, cut-off value, and determination method resulted in various Scys predictive value for AKI by subgroup analysis ([Tables 1](#t1){ref-type="table"},[2](#t2){ref-type="table"},[3](#t3){ref-type="table"},[4](#t4){ref-type="table"}). Foremost, Twenty-four hours after AKI occurrence to adopt the blood seems to be an optimal time, with sensitivity of 0.82, specificity of 0.83, DOR of 23, and AUROC of 0.89 ([Table 4](#t4){ref-type="table"}). Besides, 50% elevated from baseline could be an ideal cut-off value to predict AKI, with AUROC 0.99 ([Table 2](#t2){ref-type="table"}). Last but not the least, PETIA performed better than other two determination methods, with sensitivity 0.76, specificity 0.87 and AUROC 0.90 ([Table 3](#t3){ref-type="table"}). In addition, several factors other than Scys assay itself were also analyzed in this study, such as AKI diagnostic criteria, region, gender, age and sample size and *et al*. Based on the newly KDIGO criteria, Scys performed the best accuracy, with sensitivity 0.78, specificity 0.90 and AUROC 0.92 ([Table 3](#t3){ref-type="table"}). However, these factors mentioned above were not the origin of possible sources of heterogeneity by meta-regression analysis.

Publication bias
----------------

No publication bias and high symmetry of the included studies were proved by Deeks' funnel plot asymmetry test (*P* = 0.72; [Fig. 5](#f5){ref-type="fig"}).

Discussion
==========

The overall AKI incidence in this study was 23.1% (982/4247), similar to the prevalence reported in Siew' study4, indicating the disease is still not in control and prevented. The mean age in this meta-analysis achieved 61 years old, demonstrating more attention should be taken on the susceptible population: the elderly. Various setting, various AKI incidence. The top three settings prone to AKI were cardiovascular surgery, ICU/CCU and radiology intervention department.

Facing to the severe reality, early diagnosis is crucial to prevent and relieve the prognosis of AKI. Scys has been known to be an ideal marker to assess renal function in CKD patients[@b46][@b47]. Whether it is a satisfactory marker to predict AKI is still in debate. Thus, to comprehensively and objectively evaluate the value of Scys predicting AKI, this meta-analysis set a rigorous inclusion and exclusion criteria at the very start. One of the essential selected condition should be prospective cohort studies. After literature searching, 30 studies finally were included. The pooled sensitivity, specificity and AUROC of Scys was 0.82, 0.82 and 0.89, respectively. These diagnostic efficiency demonstrated that Scys would be an excellent bio-marker for the all-cause AKI prediction.

Further subgroups analysis indicated several influence factors should be noted. Different Scys blood sampling point-in-time, cut-off value, and determination method, different Scys predictive value for AKI. If an AKI event would occur, it could be suggested that Scys should be determined by PETIA method at 24-hours after the possible AKI event, referring the diagnostic criteria-50% elevated from baseline. Compared with the previous studies results, this advice is rational and acceptable. The blood sampling point-in-time was another focus. Among the various time point, 24-hours point after AKI might be a preferable selection.

Otherwise, factors potentially influencing Scys were also assessed in this study. Three main criteria to diagnose AKI were presented in [Table 3](#t3){ref-type="table"}. The newly KDIGO criteria performed an increased diagnostic accuracy in Thomas' study[@b48]. The subgroup analysis in this study also confirmed its superiority, that the newly KDIGO criteria showed higher specificity and AUROC than the RIFLE criteria and AKIN criteria.

As reported, the most common cause of AKI is acute tubular necrosis (ATN), which could be caused by prolonged hypotension, sepsis, surgery, nephrotoxic medications, and contrast media in hospitalized patients[@b49][@b50]. Among the three main causes of AKI in this meta-analysis, Scys performed the best accuracy in CIN-AKI. The probable reason might be that kidney injury and hemodynamic disorder induced by CIN-AKI is less serious and complicate than that by CS-AKI and ICU-AKI. CIN could be the most simple, but also the most important AKI model to ascertain the value of Scys. To our knowledge, CIN is the third leading cause of AKI in hospitalized patients[@b51][@b52]. There is a variety of novel bio-markers have been proposed to diagnose CIN. Among them, Neutrophil gelatinaseassociated lipocalin (NGAL), interleukin-18 (IL-18) and Scys are the most known promising bio-markers[@b53][@b54]. However, the former two biomarker determination method have not yet been established in clinical laboratories. Thus, according to the results of this study, Scys could be the optimal marker predicting various AKI.

It should be mentioned in the end, the same as the previous CKD studies proved[@b55], Scys was not significantly influenced by gender and age in this AKI-related study, as well. Moreover, although settings, AKI diagnostic criteria, race and assay method might play a little bit of influence on the accuracy of Scys, it did not reach statistical significance. Thus, these results above showed that Scys could be a nice marker, not only for CKD diagnosis, but for AKI prediction.

For all meta-analyses, heterogeneity is a potential problem when interpreting the results. The *I*^*2*^ statistic was 96% in our meta-analysis, indicating significant heterogeneity across the included studies. One major source of heterogeneity is the threshold effect in which different cut-offs are used in the included studies. The Spearman correlation analysis in our study indicated no threshold effect related heterogeneity exit. Furthermore, meta-regression analysis results revealed that factors potentially affecting Scys did not participate in the heterogeneity (p \> 0.05; [Table 3](#t3){ref-type="table"}). Thus, we considered that the heterogeneity may be related to additional factors, such as specified ethnicity (except from the two race in this study), kidney function, and etc. However, these factors is difficult to unify and analyze.

In summary, this meta-analysis demonstrated that Scys shows a good diagnostic performance for predicting all-cause AKI. Several factors could affect the predictive value of Scys for AKI, but not reach significant differences. More randomized controlled trials in multicenter are in need to further investigate the accuracy of Scys.

Methods
=======

Data sources and search strategy
--------------------------------

In accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines[@b56], we searched PubMed, EMBASE, Web of Science and the Cochrane Library from the inception to September 2016.

The following terms were used: "AKI, acute kidney injury, acute renal failure, acute renal insufficiency, acute renal dysfunction and cystatin C". References of the selected studies were further screened manually to identify whether additional eligible articles were available or not.

Study selection
---------------

The inclusion criteria of this study were composed of the following characteristics: (1) prospective cohort study, (2) adults, (3) sample size ≥ 30, (4) original data of sensitivity and specificity, (5) AKI diagnostic criteria. If any disagreement existed, two investigators would check and discuss about the full text.

Authors were contacted when there were incomplete or missing data. Ethics approval and patients consent were not in need for this study.

Data extraction and quality assessment
--------------------------------------

Two investigators (Z.Z.Y. and X.H.P.) independently extracted information from each article using a standardized collection form. Collected parameters included the first author, publication year, clinical setting, region, age, gender, AKI diagnostic criteria, Scys determination method, Scys cut-off value, sensitivity and specificity. Differences were resolved by consensus or the third researcher (W.H.Z.).

We investigated the methodological quality of the present study using the second version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)[@b57]. QUADAS-2 assesses the risk of bias and applicability in four domains: Patient selection (consecutive or random sample enrolled, case--control design and inappropriate exclusions avoided); Index test (blinded interpretation of the Rules); Reference standard (correctly excluded a fracture and blinded interpretation); and Flow and timing (appropriate interval between application of the Rules and reference standard, all patients received the reference standard and were included in the analysis).

Statistical analysis
--------------------

A bivariate meta-analytic approach was used to pool sensitivity, specificity, DOR, PLR, and NLR. Subsequently, the respective hierarchical summary receiver operating characteristic (HSROC) curves was constructed to plot sensitivity versus specificity, and then calculate the area under the curve. The highest Youden index (sensitivity + 1-specificity) of every included studies was chosen to end pooled in various Scys measurement times[@b58]. We used the *I*^*2*^ statistic to evaluate the heterogeneity[@b59], and the *I*^*2*^ \> 75% is supposed of significant heterogeneity, the threshold analysis and meta-regression analysis were further used to identify possible sources of heterogeneity. Publication bias was estimated by Deeks' funnel plot asymmetry test[@b60]. All the data processing and analysis were performed using the midas and metandi commands of Stata/SE version 12.0 (Stata Corp LP, College Station, TX) and Meta-Disc 1.4 for Windows (XI Cochrane Colloquium, Barcelona, Spain). QUADAS-2 quality assessment was descriptively analyzed using Review Manager 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). P \< 0.05 was considered of statistical significance.
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###### Basic characteristics of the selected AKI studies for Scys.

  Study                          Country     Clinical setting   No. of patients   AKI incidence (%)   Mean age (y)   Males (%)              Definition of AKI                     Scys assay method
  --------------------------- ------------- ------------------ ----------------- ------------------- -------------- ----------- ----------------------------------------- ---------------------------------
  Herget-Rosenthal S.[@b21]      Germany           ICU                85                51.8              66.6         63.9                      RIFLE-R                      Immunonephelometric assay
  Ling Q.[@b22]                   China            LTx                30                43.3               47           90             GFR \< 80 mL/min/1.73 m^2^                        NR
  Kato K.[@b28]                   Japan            CIN                87                20.7               67          71.3      Scr↑ \> 25% or \> 0.5 mg/dL within 48 h                PENIA
  Liang X. L.[@b23]               China             CS                132               22.0               NR           NR                      RIFLE ≥ R                               PETIA
  Haase-Fielitz. A.[@b29]       Australia           CS                100               23.0              69.5          61                      RIFLE ≥ R                     Immunonephelometric assay
  Haase M.[@b24]                Australia           CS                100               46.0               71           61                      AKIN ≥ 1                      Immunonephelometric assay
  Nejat M.[@b25]               New Zealand         ICU                318                6.0               60          61.1                     RIFLE ≥ R                               PENIA
  Briguori C.[@b26]               Italy            CIN                410                8.3               70          83.9          Scr↑ ≥ 0.3 mg/dL from baseline        Dade Behring N Latex Scys assay
  Stoto K.[@b27]                Portugal            ED                616               21.1              59.1         62.7               RIFLE ≥ R & AKIN ≥ 1                          PENIA
  Torregrosa L.[@b30]             Spain            CIN                89                13.5              62.6         75.3                     RIFLE ≥ R                     Immunonephelometric assay
                                  Spain             CS                46                30.4              68.8         73.9                     RIFLE ≥ R                     Immunonephelometric assay
  Chen T. H.[@b31]               Taiwan            CCU                150               28.7               66          75.3                     AKIN ≥ 1                                ELISA
  Liu X. L.[@b32]                 China            CIN                311               12.5              58.9         63.7                       KDIGO                                 ELISA
  Hsiao P. G.[@b33]              Taiwan            AMI                96                17.7               63          90.6                     AKIN ≥ 1                                ELISA
  Kokkoris S.[@b34]              Greece            ICU                100               36.0          49\* & 63\*       57                      RIFLE ≥ R                     Immunonephelometric assay
  Aydoğdu M.[@b35]               Turkey            ICU                151               41.2              68.1         64.9                     RIFLE ≥ R                               PENIA
  Alharazy S. M.[@b36]          Malaysia           CIN                100               11.0              60.4          79        Scr↑ ≥ 25% from baseline in 48 hours                  PENIA
  Wan Z. H.[@b16]                 China            ACLF               56                14.3               44          71.4                     AKIN ≥ 1                                PENIA
  Padhy M.[@b37]                  India            CIN                60                50.0              55.9         73.3                       KDIGO                                 ELISA
  Ghonemy T. A.[@b38]             Egypt             CS                50                34.0              44.4          64                      RIFLE ≥ R                               ELISA
  Yang H. T.[@b39]                Korea            MBI                90                34.4              49.3         85.6                     RIFLE ≥ R                     Immunoturbidimetric assay
  Prowle J. R.[@b40]            Australia          CPB                93                26.9              70\*          69                      RIFLE ≥ R                     Immunonephelometric assay
  Arun O.[@b41]                  Turkey             CS                30                53.3              71.9         73.3                       KDIGO                       Immunonephelometric assay
  Tung Y. C.[@b42]               Taiwan             ED                189               19.6              62.3         86.6                     AKIN ≥ 1                                ELISA
  Yim H.[@b18]                    Korea            BICU               97                41.2               47          80.4                     AKIN ≥ 1                                 NR
  Chen J. Z.[@b43]                China            PNE                89                31.5              48.9         66.3                     AKIN ≥ 1                                ELISA
  Liu Y. J.[@b17]                 China             CS                35                54.3              52.2         34.3                     AKIN ≥ 1                                PETIA
  Peng L.[@b44]                   China            CIN                196               14.8              70.4         68.4                       KDIGO                                 PETIA
  Gong M. M.[@b45]                China            ICU                176               40.3              55.1         61.9                       KDIGO                                 ELISA
  GaygIsIz U.[@b19]              Turkey            ICU                72                26.4              64.6         72.2                     RIFLE ≥ R                               PENIA
  Martensson J.[@b20]           Australia          ICU                93                22.6          50\* & 66\*       71                        KDIGO                                 PETIA

Abbreviations: ACLE, acute-on-chronic liver failure; AMI, acute myocardial infarction; AKI, acute kidney injury; BICU, burn intensive care unit; CCU, coronary care unit; CIN, contrast-induced nephropathy; CPB, cardiopulmonary bypass; CS, cardiac surgery; ED, emergency department; ELISA, enzyme-linked immunosorbent assay; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; LTx, liver transplantation; MBI, major burn injury; NR, not reported; PENIA, particle-enhanced nephelometric immunoassay; PETIA, particle-enhanced turbidimetric immunoassay; PNE, Partial nephrectomy; RIFLE, risk-injury-failure-loss-end stage renal disease; Scr, serum creatinine; Scys, serum cystatin C.

\*Median age (year).

###### The accuracy of Scys at various blood sampling point-in-time and cut-off value.

  Study                               Blood sampling point-in-time            Scys cutoff value     Test results   Sensitivity (%)   Specificity (%)   AUROC (95% CI)                  
  --------------------------- -------------------------------------------- ----------------------- -------------- ----------------- ----------------- ---------------- ------- ------- -------------------
  Herget-Rosenthal S.[@b21]            On day after kidney injury           ↑ ≥ 50% from baseline        43               3                 1                38          98      93     0.99(0.98, 1.00)
                                       24 h before kidney injury            ↑ ≥ 50% from baseline        36               2                 8                39          82      95     0.97(0.94, 0.99)
                                       24 h before kidney injury            ↑ ≥ 50% from baseline        24               2                20                39          55      95     0.82(0.71, 0.92)
  Ling Q.[@b22]                            Post-Tx d 1,4, &7                      1.57 mg/L              11               3                 2                14         84.6    84.5    0.94(0.86, 0.98)
  Kato K.[@b28]                 Before,1,2,3 days after catheterization           1.2 mg/L               17              10                 1                59         94.7    84.8          0.93
  Liang X. L.[@b23]                         Postoperative d1                ↑ ≥ 50% from baseline        27               5                 2                98          92      95     0.99(0.98, 1.01)
  Haase-Fielitz A.[@b29]                    On ICU admission                      1.1 mg/L               18              11                 5                66          77      86     0.83(0.68, 0.98)
                                             24 h after CPB                       1.2 mg/L               21              28                 2                49          91      64     0.84(0.75, 0.93)
  Haase M.[@b24]                             6 h after CPB                        1.1 mg/L               34              18                12                36          74      67     0.76(0.61, 0.91)
  Nejat M.[@b25]                            On ICU admission                      0.8 mg/L               18              123                1               176          95      59     0.80(0.71, 0.88)
  Briguori C.[@b26]                      24 h after CM exposure             ↑ ≥ 10% from baseline        34              53                 0               323          100    85.9          0.92
  Soto K[@b27]                              On ED admission                       0.98 mg/L             106              113               24               373         81.4    76.7    0.87(0.83, 0.90)
                                         6 h after ED admission                   0.98 mg/L             106              112               24               374         81.6    77.0    0.87(0.83, 0.91)
                                        12 h after ED admission                   0.98 mg/L             106              104               24               382         81.6    78.5    0.88(0.84, 0.91)
                                        24 h after ED admission                   0.98 mg/L             103              109               27               377         79.5    77.5    0.86(0.82, 0.90)
                                        48 h after ED admission                   0.98 mg/L             105              97                25               389          81     80.1    0.87(0.83, 0.91)
  Torregrosa L.[@b30]                        12 h after CAG                       0.8 mg/L               11              18                 1                59          89      76     0.87(0.68, 1.06)
                                             12 h after CS                        0.8 mg/L               9               12                 5                20          64      64     0.68(0.46, 0.88)
  Chen T. H.[@b31]                          On CCU admission                      1.8 mg/L               33              10                10                97          77      91     0.90(0.83, 0.96)
  Liu X. L.[@b32]                        On hospital admission                    475 ng/mL              22              54                17               218         57.1    80.1    0.63(0.53, 0.73)
                                      24 h after CM administration                503 ng/mL              22              108               17               164         57.1    60.2    0.63(0.54, 0.72)
  Hsiao P. G.[@b33]                     On 24 h of AMI after PCI                  1364 mg/L              12              11                 5                68         69.2    85.9          0.864
  Kokkoris S.[@b34]                         On ICU admission                      1.04 mg/L              22              12                14                52         61.1    81.2    0.75(0.65, 0.83)
  Aydoğdu M.[@b35]                 Within first 24 h of ICU admission             1.5 mg/L               46              28                17                60          73      68           0.82
  Alharazy S. M.[@b36]                 At 24 h after CM exposure                  0.19 mg/L              7               10                 4                79         63.64   88.76   0.80(0.70, 0.87)
  Wan Z. H.[@b16]                         On Center admission                     1.21 mg/L              8                6                 0                42          100    87.5    0.97(0.85, 1.00)
  Padhy M.[@b37]                      0 h of angioplasty procedure               0.504 mg/L              20              11                10                19          66      63           0.70
                                      4 h of angioplasty procedure               0.517 mg/L              20              10                10                20         66.7    66.6          0.72
                                     24 h of angioplasty procedure               0.994 mg/L              30               1                 0                29          100    96.7          1.00
                                     48 h of angioplasty procedure               0.961 mg/L              28               1                 2                29         93.3    96.7          0.99
  Ghonemy T. A.[@b38]                         3 h after CS                       2.65 ng/dL              9                9                 8                24         54.7    72.7           NR
                                              6 h after CS                       2.65 ng/dL              13               8                 4                25         75.2    75.8           NR
  Yang H. T.[@b39]                        12 h from admission                     0.70 mg/L              22              21                 9                38         70.4    65.2          0.75
                                          24 h from admission                     0.75 mg/L              16              23                15                36         50.0    61.8          0.73
  Prowle J. R.[@b40]                        4.5 h after CPB                       1.24 mg/L              19              25                 6                43         76.0    63.2    0.69(0.56, 0.82)
                                             24 h after CPB                       1.57 mg/L              16              15                 9                53         64.0    77.9    0.72(0.59, 0.85)
  Arun O.[@b41]                             At 1 h after CS                      0.76 mg/dL              12               5                 4                9           75      65           0.74
                                            At 12 h after CS                     0.98 mg/dL              12               3                 4                11          75      80           0.77
                                            At 24 h after CS                     0.83 mg/dL              15               3                 1                11          93      79           0.79
                                            At 48 h after CS                     0.73 mg/dL              13               4                 3                10          81      72           0.72
  Tung Y. C.[@b42]                          On ED admission                       1.6 mg/L               29              47                 8               105          79      69     0.73(0.63, 0.81)
  Yim H.[@b18]                             At 7 d after Burn                      0.75 mg/L              31              14                 9                43         76.3    75.4    0.81(0.71, 0.91)
                                           At 14 d after Burn                     0.85 mg/L              36              10                 4                47         89.5    82.5    0.91(0.84, 0.97)
  Chen J. Z.[@b43]                         At 24 h after PNE                      0.98 mg/L              20              16                 8                45         71.4    73.8    0.79(0.70, 0.89)
                                           At 48 h after PNE                     1.005 mg/L              19              21                 9                40         67.9    65.6    0.76(0.66, 0.86)
  Liu Y. J.[@b17]                             0 h after CS                       0.965 mg/L              14               4                 5                12         73.7    75.0    0.74(0.57, 0.91)
                                              4 h after CS                       1.150 mg/L              15               4                 4                12         78.9    75.0    0.86(0.74, 0.98)
                                             24 h after CS                       1.275 mg/L              18               2                 1                14         94.7    87.5    0.97(0.97, 1.02)
                                             48 h after CS                       1.405 mg/L              18               2                 1                14         94.7    87.5    0.97(0.93, 1.02)
                                             72 h after CS                       1.380 mg/L              18               3                 1                13         94.7    81.2    0.94(0.87, 1.02)
  Peng L.[@b44]                              24 h after PCI                 ↑ ≥ 15% from baseline        10              10                19               157         34.48   94.01   0.66(0.55, 0.77)
                                             48 h after PCI                 ↑ ≥ 15% from baseline        12              12                17               155         41.38   92.86   0.78(0.70, 0.87)
  Gong M. M.[@b45]                          On ICU admission                      1.54 mg/L              54               4                17               101         76.1    96.2    0.90(0.86, 0.95)
  GaygIsIz U[@b19]             within the first 24--48 h of ICU admission         0.94 mg/L              12              18                 7                35          63      66     0.67 (0.53, 0.81)
  Martensson J.[@b20]                 within 48 h of ICU admission                1.1 mg/l               12              17                 9                55          55      76     0.67 (0.54-0.81)

Abbreviations: AKI, acute kidney injury; AUROC, the area under the receiver operating characteristic curve; CAG, coronary angiography; CM, contrast medium; CPB, cardiopulmonary bypass; CS, cardiac surgery; DOR, diagnostic odds ratio; Scys, serum cystatin C; TP, true positive; FP, false positive; FN, false negative; TN, true negative; Tx, transplant; ICU, intensive care unit; ED, emergency department; PCI, percutaneous coronary intervention; PNE, Partial nephrectomy; NR, not reported.

###### Pooled diagnostic accuracy of Scys in various AKI subgroup studies.

  Settings                      AKI Pts/Total Pts; No. of studies   Sensitivity (95% CI)   Specificity (95% CI)   DOR (95% CI)    AUROC (95% CI)     *I*^*2*^   Likelihood Ratio (95% CI)         RDOR               P Value       
  ---------------------------- ----------------------------------- ---------------------- ---------------------- -------------- ------------------- ---------- --------------------------- ------------------- ------------------- -------
  Across all settings                     982/4247; 30               0.82 (0.75, 0.87)      0.82 (0.78, 0.86)     21 (12, 35)    0.89 (0.86, 0.91)      96           4.6 (3.6, 5.9)         0.22 (0.16, 0.31)                          
  Subgroups                                                                                                                                                                                                                            
  1.AKI setting:                                                                                                                                                                                                                   
   CS-AKI                                  189/586; 8                0.81 (0.71, 0.89)      0.82 (0.72, 0.89)      20 (7, 57)    0.89 (0.86, 0.91)      0            4.5 (2.7, 7.8)         0.23 (0.13, 0.39)   1.49 (0.65, 3.40)   0.327
   ICU/CCU-AKI                             340/1194; 9               0.77 (0.66, 0.85)      0.82 (0.72, 0.89)      16 (6, 38)    0.86 (0.83, 0.89)      89           4.3 (2.5, 7.4)         0.28 (0.18, 0.44)                          
   CIN                                     173/1253; 7               0.90 (0.61, 0.98)      0.87 (0.82, 0.90)     61(10, 388)    0.90 (0.88, 0.93)      95           6.7 (4.7, 9.7)         0.11 (0.02, 0.57)                          
   CIN                                     173/1253; 7               0.90 (0.61, 0.98)      0.87 (0.82, 0.90)     61(10, 388)    0.90 (0.88, 0.93)      95           6.7 (4.7, 9.7)         0.11 (0.02, 0.57)   2.24 (0.65, 7.79)   0.194
   Exp-CIN                                809/2994; 23               0.79 (0.74, 0.84)      0.81 (0.75, 0.85)      16(10, 26)    0.87 (0.84, 0.89)      85           4.1 (3.1, 5.4)         0.26 (0.20, 0.34)                          
  2.AKI diagnostic criteria:                                                                                                                                                                                                       
   KDIGO                                   206/866; 6                0.78 (0.49, 0.93)      0.90 (0.81, 0.95)     31 (6, 174)    0.92 (0.90, 0.94)      77           7.7 (3.4, 17.7)        0.25 (0.09, 0.70)   0.60 (0.29, 1.22)   0.147
   AKIN ≥ 1                                238/812; 8                0.81 (0.74, 0.86)      0.81 (0.74, 0.87)      18 (9, 35)    0.86 (0.83, 0.89)      0            4.3 (3.0, 6.4)         0.24 (0.17, 0.34)                          
   RIFLE ≥ R                              284/1241; 11               0.75 (0.67, 0.82)      0.76 (0.67, 0.82)      10 (5, 18)    0.82 (0.72, 0.85)      64           2.1 (2.2, 4.4)         0.32 (0.23, 0.46)                          
  3.region:                                                                                                                                                                                                                        
   Asia                                   578/2197; 20               0.81 (0.73, 0.87)      0.85 (0.80, 0.89)     24 (12, 45)    0.90 (0.87, 0.92)      93           5.3 (3.8, 7.5)         0.23 (0.15, 0.33)   1.69 (0.60, 4.78)   0.307
   Non-Asia                               404/2050; 10               0.83 (0.70, 0.91)      0.78 (0.71, 0.83)      17 (7, 43)    0.85 (0.82, 0.88)      82           3.7 (2.7, 5.2)         0.22 (0.11, 0.42)                          
  4.Scys assay:                                                                                                                                                                                                                    
   PETIA                                   129/546; 5                0.76 (0.51, 0.91)      0.87 (0.74, 0.94)     21 (4, 103)    0.90 (0.87, 0.92)      88           5.8 (2.5, 13.5)        0.27 (0.11, 0.67)   1.21 (0.56, 2.60)   0.614
   PENIA                                  484/2043; 14               0.82 (0.31, 0.81)      0.78 (0.72, 0.83)      16 (8, 31)    0.86 (0.83, 0.89)      62           3.8 (2.8, 5.0)         0.24 (0.15, 0.37)                          
   ELISA                                   282/1121; 8               0.77 (0.66, 0.85)      0.86 (0.77, 0.92)      21 (8, 55)    0.88 (0.85, 0.90)      72           5.6 (3.0, 10.3)        0.27 (0.17, 0.42)                          
  5.participant mean age:                                                                                                                                                                                                          
   ≤60 years                              445/1928; 12               0.85 (0.75, 0.91)      0.82 (0.74, 0.88)     26 (11, 61)    0.90 (0.87, 0.93)      89           4.8 (3.1, 7.4)         0.19 (0.11, 0.33)   1.24 (0.43, 1.56)   0.684
   \>60 years                             451/1994; 15               0.80 (0.70, 0.88)      0.82 (0.76, 0.88)      18 (9, 36)    0.88 (0.84, 0.90)      93           4.4 (3.2, 5.9)         0.24 (0.15, 0.38)                          
  6.male rate:                                                                                                                                                                                                                     
   ≤70%                                   604/2512; 14               0.78 (0.67, 0.86)      0.83 (0.78, 0.88)      18 (9, 36)    0.88 (0.85, 0.91)      94           4.7 (3.4, 6.5)         0.26 (0.17, 0.41)   0.96 (0.37, 2.49)   0.925
   \>70%                                  349/1603; 15               0.83 (0.75, 0.90)      0.80 (0.73, 0.85)     20 (10, 41)    0.88 (0.85, 0.91)      77           4.1 (3.0, 5.7)         0.21 (0.13, 0.33)                          
  7.sample size:                                                                                                                                                                                                                   
   ≤100                                   488/1598; 20               0.82 (0.74, 0.88)      0.81 (0.77, 0.85)     20 (10, 39)    0.88 (0.85, 0.91)      42           4.4 (3.3, 5.8)         0.22 (0.14, 0.33)   0.59 (0.21, 1.65)   0.304
   \>100                                  494/2649; 10               0.81 (0.67, 0.89)      0.85 (0.76, 0.91)     23 (10, 54)    0.90 (0.87, 0.92)      96           5.3 (3.3, 8.6)         0.23 (0.13, 0.40)                          

Abbreviations: AKI, acute kidney injury; AUROC, the area under the receiver operating characteristic curve; CCU, coronary care unit; CIN, contrast-induced nephropathy; CS, cardiac surgery; DOR, diagnostic odd ratio; ELISA, enzyme-linked immunosorbent assay; KDIGO, Kidney Disease: Improving Global Outcomes; PENIA, particle-enhanced nephelometric immunoassay; PETIA, particle-enhanced turbidimetric immunoassay; Pts, patients; RIFLE, risk-injury-failure-loss-end stage renal disease; Scr, serum creatinine; Scys, serum cystatin C.

###### Diagnostic accuracy of Scys in predicting AKI at different time points.

  Time                              Study number   Sensitivity (95% CI)   Specificity (95% CI)   DOR (95% CI)   *I*^*2*^    AUROC (95% CI)
  -------------------------------- -------------- ---------------------- ---------------------- -------------- ---------- -------------------
  All settings 0 h                       12         0.79 (0.70, 0.86)      0.82 (0.74, 0.88)      17 (9, 35)       92      0.88 (0.84, 0.90)
  1--12 h                                9          0.75 (0.70, 0.80)      0.72 (0.68, 0.76)       8 (5,12)        0       0.80 (0.76, 0.83)
  24 h                                   16         0.82 (0.69, 0.90)      0.83 (0.76, 0.89)      23 (9, 57)       95      0.89 (0.86, 0.92)
  48 h                                   7          0.76 (0.60, 0.88)      0.87 (0.76, 0.93)      21 (5, 58)       94      0.89 (0.86, 0.92)
  1--6 h after cardiac surgery           5          0.73 (0.65, 0.80)      0.68 (0.62, 0.74)       6 (4, 9)       100      0.77 (0.73, 0.80)
  12--24 h after cardiac surgery         6          0.85 (0.72, 0.92)      0.80 (0.68, 0,89)      23 (7, 77)       7       0.90 (0.87, 0.92)

Abbreviations: AKI, acute kidney injury; AUROC, the area under the receiver operating characteristic curve; DOR, diagnostic odds ratio; Scys, serum cystatin C.

[^1]: These authors contributed equally to this work.
